Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Berenberg Bank analyst maintained a Buy rating on AstraZeneca yesterday and set a price target of $95.00. The company’s shares closed yesterday at $95.16.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $102.40 average price target.
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $15.19 billion and a net profit of $2.53 billion. In comparison, last year the company earned a revenue of $13.57 billion and had a net profit of $1.43 billion
Read More on AZN:
Disclaimer & DisclosureReport an Issue
- LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
- AstraZeneca: Broad Late-Stage Pipeline, Emerging Obesity Franchise, and Autoimmune CAR-T Platform Support Upside and Buy Rating
- AstraZeneca price target raised to 16,500 GBp from 14,000 GBp at Barclays
- AstraZeneca announces results of Saphnelo were statistically significant
- Kennedy scales back number of vaccines recommended for children, NYT says
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.